(122 days)
Indicated for use by health care professionals whenever there is a need for monitoring the physiological parameters of patients. Intended for monitoring and recording of and to generate alarms for multiple physiological parameters of adults, pediatrics and neonates in hospital environments. The MP2, MP5, MP5T, MP5SC, X2, MP20, MP30, MP40, and MP50 are additionally intended for use in transport situations within hospital environments. The MP2, X2 and MP5 are also intended for use during patient transport outside of a hospital environment.
The Integrated Pulmonary Index (IPI) is intended for use with adult and pediatric (1 to 12 years) patients only. The IPI is an adjunct to and not intended to replace vital sign monitoring.
The Philips IntelliVue Patient Monitor family comprises the multi-parameter patient monitor models MP2, X2, MP5, MP5SC, MP20, MP30, MP40, MP50, MP60, MP70, MP80, MP90, MX600, MX700 and MX800 Patient Monitors which consist of display units IntelliVue including build-in or separate flat panel displays and central processing units as well as physiological measurement modules. All monitors share the same system architecture and exactly the same software is executed on each. The Patient Monitor family is a flexible and modular monitoring solution optimized for the surgical, cardiac, general medical and neonatal care environments. The monitors can be connected to the Philips Multi-Measurement Module (MMS) family with its extensions to the IntelliVue family plug-in measurement modules. The and monitors can also be connected to the IntelliVue anesthetic gas modules and to the IntelliVue TcG10 Measurement Module.
The subject modification is the introduction of the Integrated Pulmonary Index (IPI) software module as an extension to the legally marketed Microstream CO2 measurement module as integrated or interfaced to the Patient Monitor family.
The IPI is a numerical integer value ranging from 1 to 10. It is calculated based on the four major parameters from the monitoring of the physiological parameters CO2 and SpO2 in order to provide a simple and clear single parameter indication of the patient's ventilation status. These four major parameters are etCO2 and Respiration Rate (RR) which are received from the Microstream CO2 measurement module, as well as SpO2 and Pulse Rate (PR) which are received from the pulse oximetry module of the host system.
The Philips MP2, X2, MP5, MP5SC, MP20, MP30, MP40, MP50, MP60, MP70, MP80, MP90, MX600, MX700, and MX800 IntelliVue Patient Monitors, with the Integrated Pulmonary Index (IPI) software module, underwent verification and validation testing to establish their safety, performance, functionality, and reliability.
1. Acceptance Criteria and Reported Device Performance:
The provided document states that "Pass/Fail criteria were based on the specifications cleared for the predicate devices." However, the specific quantitative acceptance criteria for the IPI software module or the overall patient monitor performance are not explicitly detailed in the provided text. The document concludes: "The results demonstrate that the modified Philips MP2, X2, MP5, MP5T, MP5SC, MP20, MP30, MP40, MP50, MP60, MP70, MP80, MP90, MX600, MX700 and MX800 IntelliVue Patient Monitors are as safe and as effective and perform as the predicate devices."
Therefore, based on the provided text, the table is as follows:
| Acceptance Criteria | Reported Device Performance |
|---|---|
| Based on specifications cleared for predicate devices (specific criteria not detailed) | Device demonstrated to be "as safe and as effective and perform as the predicate devices." |
2. Sample Size and Data Provenance for the Test Set:
This information is not provided in the document. The text mentions "Verification and validation testing activities were conducted," but does not specify the sample size used for the test set or the data provenance (e.g., country of origin, retrospective/prospective nature).
3. Number of Experts and their Qualifications for Ground Truth of the Test Set:
This information is not provided in the document.
4. Adjudication Method for the Test Set:
This information is not provided in the document.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study:
An MRMC comparative effectiveness study is not mentioned in the document. The study described focuses on the comparison of the modified device to predicate devices in terms of safety and effectiveness, rather than evaluating human reader improvement with AI assistance.
6. Standalone (Algorithm Only) Performance Study:
A standalone performance study of the IPI algorithm without human-in-the-loop is not explicitly detailed as a separate study. The IPI is described as a software module that provides a simple indication of ventilation status based on physiological parameters. The V&V testing would inherently involve evaluating the IPI's calculations and output, which could be considered a form of standalone evaluation of its functionality. However, a dedicated 'standalone performance study' with specific metrics for the IPI algorithm's accuracy in isolation is not described.
7. Type of Ground Truth Used:
The document states that the IPI calculation is based on "four major parameters from the monitoring of the physiological parameters CO2 and SpO2," specifically "etCO2 and Respiration Rate (RR) which are received from the Microstream CO2 measurement module, as well as SpO2 and Pulse Rate (PR) which are received from the pulse oximetry module of the host system." This suggests that the ground truth for evaluating the IPI's calculation would be derived from the measurements of these established physiological parameters from the integrated modules. It does not mention expert consensus, pathology, or outcomes data as direct ground truth for the IPI itself, but rather the accurate processing of existing physiological data.
8. Sample Size for the Training Set:
This information is not provided in the document. The document refers to the IPI as a "software module" and its calculation, but does not describe it as a machine learning or AI model that requires a distinct training set in the conventional sense.
9. How the Ground Truth for the Training Set Was Established:
As the document does not describe a distinct training set, this information is not applicable/provided. The IPI appears to be a deterministic calculation based on established physiological parameters rather than a learned model.
{0}------------------------------------------------
510(k) Summary K113 44/ 8.
This summary of 510(k) safety and effectiveness information is submitted in accordance with the requirements of the Safe Medical Devices Act of 1990 and 21 C.F.R. $807.92.
- The submitter of this premarket notification is:
Dr. Jens-Peter Seher Philips Medizin Systeme Boeblingen GmbH Hewlett-Packard-Str. 2 D-71034 Boeblingen, Germany Tel: ++49 7031 463-2086 Fax: ++49 7031 463-2442 e-mail: jens-peter.seher@philips.com
This summary was prepared on November 17, 2011.
- The names of the devices are: Trade Name: Philips MP2, X2, MP5, MP5SC, MP20, MP30, MP40, MP50, MP60, MP70, MP80, MP90, MX600, MX700 and MX800 IntelliVue patient monitors .
Common name: Multiparameter Patient Monitor
{1}------------------------------------------------
Classification names are as follows:
| Device Panel | Classification | ProCode | Description |
|---|---|---|---|
| CardiovascularDevices | $870.1025, II | DSI | Detector and alarm, arrhythmia |
| $870.1025, II | MLD | Monitor, ST Segment with Alarm | |
| $870.1025, II | MHX | Monitor, Physiological, Patient(with arrhythmia detection oralarms) | |
| $870.1100, II | DSJ | Alarm, Blood Pressure | |
| $870.1110, II | DSK | Computer, Blood Pressure | |
| $870.1130, II | DXN | System, Measurement, Blood-Pressure, Non-Invasive | |
| $870.1435, II | DXG | Computer, Diagnostic, Pre-Programmed, Single-Function | |
| $870.1915, II | KRB | Probe, Thermodilution | |
| $870.2060, II | DRQ | Amplifier and SignalConditioner, Transducer Signal | |
| $870.2300, II | DRT | Monitor, Cardiac (incl.Cardiotachometer & Rate Alarm) | |
| $870.2340, II | DPS | Electrocardiograph | |
| $870.2340, II | MLC | Monitor, ST Segment | |
| $870.2350, II | DRW | Electrocardiograph, LeadSwitching Adapter | |
| $870.2370, II | KRC | Tester, Electrode, Surface,Electrocardiograph | |
| $870.2600, I | DRJ | System, Signal Isolation | |
| $870.2700, II | DQA | Oximeter | |
| $870.2770, II | DSB | Plethysmograph, Impedance | |
| $870.2800, II | DSH | Recorder, Magnetic tape,Medical | |
| $870.2810, I | DSF | Recorder, Paper Chart | |
| $870.2850, II | DRS | Extravascular Blood PressureTransducer | |
| $870.2900, I | DSA | Cable, Transducer andElectrode, incl. PatientConnector | |
| - | MSX | System, Network andCommunication, PhysiologicalMonitors | |
| $870.2910, II | DRG | Transmitters and Receivers,Physiological Signal,Radiofrequency | |
| AnesthesiologyDevices | $868.1400, II | CCK | Analyzer, Gas, Carbon Dioxide,Gaseous-Phase |
| $868.1500, II | CBQ | Analyzer, Gas, Enflurane,Gaseous-Phase (AnestheticConcentration) | |
| $868.1500, II | NHO | Analyzer, Gas, Desflurane,Gaseous-Phase (AnestheticConcentration) | |
| $868.1500, II | NHP | Analyzer, Gas, Sevoflurane,Gaseous-Phase (AnestheticConcentration) | |
| $868.1500, II | NHQ | Analyzer, Gas, Isoflurane,Gaseous-Phase (AnestheticConcentration) | |
| Device Panel | Classification | ProCode | Description |
| $868.1620, II | CBS | Analyzer, Gas, Halothane,Gaseous-Phase (AnestheticConcentration) | |
| $868.1700, II | CBR | Analyzer, Gas, Nitrous Oxide,Gaseous-Phase (AnestheticConcentration) | |
| $868.1720, II | CCL | Analyzer, Gas, Oxygen, Gaseous-Phase | |
| $868.1880, II | BZC | Data calculator Pulmonary-function | |
| $868.2375, II | BZQ | Monitor, Breathing Frequency | |
| $868.2480, II | LKD | Monitor, Carbon Dioxide,Cutaneous | |
| $868.2500, II | KLK | Monitor, Oxygen, Cutaneous, forInfant not under Gas Anesthesia | |
| General Hospitaland Personal UseDevices | $880.2910, II | FLL | Thermometer, Electronic,Clinical |
| NeurologicalDevices | $882.1400, II | GWR | Electroencephalograph |
| $882.1420, I | GWS | Analyzer, Spectrum,Electroencephalogram Signal |
{2}------------------------------------------------
-
- The modified Philips MP2, X2, MP5, MP5SC, MP30, MP40, MP50, MP60, MP70, MP80, MX600, MX700 and MX800 IntelliVue Patient monitors are substantially equivalent to previously cleared Philips IntelliVue patient monitors marketed pursuant to: K110622, K110474, K102562, K101449, K100939, K093268, K091927, K083517, K082633, K081793, K072070, K071426, K063725, K063315, K062283, K062392, K061610, K061052, K060541, K060221, K053522, K052801, K051106, K050762, K050141, K042845, K041235, K040304, K033513, K033444, K032858, K031481, K030038, K023871, and K021778 .
-
- Description of the devices
The Philips IntelliVue Patient Monitor family comprises the multi-parameter patient monitor models MP2, X2, MP5, MP5SC, MP20, MP30, MP40, MP50, MP60, MP70, MP80, MP90, MX600, MX700 and MX800 Patient Monitors which consist of display units IntelliVue including build-in or separate flat panel displays and central processing units as well as physiological measurement modules. All monitors share the same system architecture and exactly the same software is executed on each. The Patient Monitor family is a flexible and modular monitoring solution optimized for the surgical, cardiac, general medical and neonatal care environments. The monitors can be connected to the
Philips Multi-Measurement Module (MMS) family with its extensions to the IntelliVue family plug-in measurement modules. The and monitors can also be connected to the IntelliVue anesthetic gas modules and to the IntelliVue TcG10 Measurement Module.
{3}------------------------------------------------
The subject modification is the introduction of the Integrated Pulmonary Index (IPI) software module as an extension to the legally marketed Microstream CO2 measurement module as integrated or interfaced to the Patient Monitor family.
The IPI is a numerical integer value ranging from 1 to 10. It is calculated based on the four major parameters from the monitoring of the physiological parameters CO2 and SpO2 in order to provide a simple and clear single parameter indication of the patient's ventilation status. These four major parameters are etCO2 and Respiration Rate (RR) which are received from the Microstream CO2 measurement module, as well as SpO2 and Pulse Rate (PR) which are received from the pulse oximetry module of the host system.
The IPI is available for all three groups of pediatric patients (1 - 3 years, 3 - 6 years, and 6 - 12 years) and for adult patients. It is not available for Neonatal/ Infant patients (patients up to the age of one year).
-
- Indications for Use
Indicated for use by health care professionals whenever there is a need for monitoring the physiological parameters of patients. Intended for monitoring and recording of and to generate alarms for multiple physiological parameters of adults, pediatrics and neonates in hospital environments. The MP2, MP5, MP5T, MP5SC, X2, MP20, MP30, MP40, and MP50 are additionally intended for use in transport situations within hospital environments. The MP2, X2 and MP5 are also intended for use during patient transport outside of a hospital environment.
- Indications for Use
The Integrated Pulmonary Index (IPI) is intended for use with adult and pediatric (1 to 12 years) patients only. The IPI is an adjunct to and not intended to replace vital sign monitoring.
6. Technological characteristics
The modified devices have the same substantial technological characteristics, such as fundamental design, user interface, materials, energy source, and measurement technology, as the legally marketed predicate devices.
{4}------------------------------------------------
-
- Summary and conclusion
Verification and validation testing activities were conducted to establish the safety, performance, functionality, and reliability characteristics of the modified devices with respect to the predicate devices.
- Summary and conclusion
V&V testing were executed including, safety, functionality and regression testing and testing from the hazard analysis. Pass/Fail criteria were based on the specifications cleared for the predicate devices.
The results demonstrate that the modified Philips MP2, X2, MP5, MP5T, MP5SC, MP20, MP30, MP40, MP50, MP60, MP70, MP80, MP90, MX600, MX700 and MX800 IntelliVue Patient Monitors are as safe and as effective and perform as the predicate devices.
The modified devices are substantially equivalent in intended use and fundamental technological characteristics compared to the appropriate predicate devices. The modified devices introduce no new questions concerning the safety or effectiveness and are, therefore, substantially equivalent to the predicate devices.
{5}------------------------------------------------
Image /page/5/Picture/0 description: The image shows the seal of the U.S. Department of Health & Human Services. The seal features a stylized caduceus, a symbol often associated with medicine and healthcare, with three parallel lines forming a stylized representation of a staff with a serpent entwined around it. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the caduceus.
DEPARTMENT OF HEALTH & HUMAN SERVICES
MAR 2 2 2012
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
Dr. Jens-Peter Seher Philips Medizin Systeme Boeblingen GmbH Hewlett-Packard-Str. 2 Boeblingen Germany D 71034
Re: K113441
Trade/Device Name: Philips MP2, X2, MP5, MP5SC, MP20, MP30, MP40, MP50, MP60, MP70, MP80, MP90, MX600, MX700 and MX800 Intelli Vue Patient Monitors
Regulation Number: 21 CFR 870.1025
Regulation Name: Arrhythmia Detector and Alarm (Including ST-segment measurement and alarm).
Regulatory Class: II Product Code: MHX Dated: February 28, 2012 Received: March 5, 2012
Dear Dr. Seher:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{6}------------------------------------------------
Page 2 - Dr. Seher
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices /ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
hr for.
Anthony D. Watson, B.S., M.S., M.B.A. Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{7}------------------------------------------------
Indications for Use
510(k) Number (if known):
Device Name: Philips MP2, X2, MP5, MP5SC, MP20, MP30, MP40, MP50, MP60, MP70, MP80, MX600, MX700 and MX800 IntelliVue patient monitors, software revision J.01.
Indications for Use:
Indicated for use by health care professionals whenever there is a need for monitoring the physiological parameters of patients. Intended for monitoring and recording of and to generate alarms for multiple physiological parameters of adults, pediatrics and neonates in hospital environments. The MP2, MP5, MP5T, MP5SC, X2, MP20, MP30, MP40, and MP50 are additionally intended for use in transport situations within hospital environments. The MP2, X2 and MP5 are also intended for use during patient transport outside of a hospital environment.
The Integrated Pulmonary Index (IPI) is intended for use with adult and pediatric (1 to 12 years) patients only. The IPI is an adjunct to and not intended to replace vital sign monitoring.
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use AND/OR (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE
OF NEEDED)
urrence of CDRH, Office of Device Evaluation (ODE)
(Division Sign-Off) Division of Anesthesiology, General Hospital Infection Control, Dental Device
510(k) Number. k113
Page 17
§ 870.1025 Arrhythmia detector and alarm (including ST-segment measurement and alarm).
(a)
Identification. The arrhythmia detector and alarm device monitors an electrocardiogram and is designed to produce a visible or audible signal or alarm when atrial or ventricular arrhythmia, such as premature contraction or ventricular fibrillation, occurs.(b)
Classification. Class II (special controls). The guidance document entitled “Class II Special Controls Guidance Document: Arrhythmia Detector and Alarm” will serve as the special control. See § 870.1 for the availability of this guidance document.